ezetimibe has been researched along with Acute Coronary Syndrome in 102 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (0.98) | 29.6817 |
| 2010's | 72 (70.59) | 24.3611 |
| 2020's | 29 (28.43) | 2.80 |
| Authors | Studies |
|---|---|
| Blazing, MA; Braunwald, E; Cannon, CP; Giugliano, RP; Oyama, K; Park, JG; Sabatine, MS; Tershakovec, AM | 1 |
| Hata, Y; Higashino, N; Iida, O; Ishihara, T; Mano, T; Nakao, S; Toyoshima, T; Tsujimura, T | 1 |
| Colivicchi, F; Di Fusco, SA; Macchiusi, A; Spinelli, A | 1 |
| Jia, Y; Martinez, L; Sanchez, SZ; Wang, X; Xi, X; Xie, W; Zhao, Q | 1 |
| Bhatt, DL; Bittner, VA; Diaz, R; Dilic, M; Goodman, SG; Jukema, JW; Landmesser, U; Loy, M; McGinniss, J; Pećin, I; Pordy, R; Poulsen, SH; Schwartz, GG; Steg, PG; Szarek, M; White, HD | 1 |
| Annibali, G; Aranzulla, T; Bianchi, F; Blandino, A; Bongioanni, S; Borrione, M; Carceri, C; Casati, R; Cerutti, E; Civera, S; Colopi, M; De Rosa, C; Delnevo, F; Gandolfo, N; Gasco, A; Giglio, C; Grossi, S; Luceri, S; Mabritto, B; Meliga, E; Muccioli, S; Musumeci, G; Parrini, I; Pizzuti, A; Scrocca, I; Sibona Masi, A; Tomasello, A | 1 |
| Hao, Y; Li, J; Wang, YC; Yang, YL | 1 |
| Abdennbi, K; Angoulvant, D; Kownator, S; Lebeau, F; Meltz, M; Puymirat, E; Sabouret, P; Schiele, F | 1 |
| Blazing, MA; Braunwald, E; Cannon, CP; Giugliano, RP; Jarolim, P; Marston, NA; Morrow, DA; Park, JG; Patel, SM; Qamar, A | 1 |
| Giugliano, RP; Oliver, W | 1 |
| Bilato, C; Caldarola, P; Colivicchi, F; Musumeci, G | 1 |
| Hu, WS; Lin, CL; Yu, TS | 1 |
| Elgendy, IY; Mansoor, H; Ya'Qoub, L | 1 |
| Banach, M; Bielecka-Dąbrowa, A; Desperak, P; Dudek, D; Dyrbuś, K; Gąsior, M; Gierlotka, M; Jankowski, P; Lewek, J; Niedziela, J; Osadnik, T; Witkowski, A | 1 |
| Aimaitijiang, M; Deng, CJ; Hou, XG; Pan, Y; Sirajidin, S; Wang, SF; Wu, TT; Xie, X; Yan, J; Zheng, YY | 1 |
| Arashi, H; Hagiwara, N; Haruta, S; Ishii, Y; Kawada-Watanabe, E; Koyanagi, R; Mori, F; Murasaki, S; Ogawa, H; Sekiguchi, H; Suzuki, K; Yamaguchi, J; Yamauchi, T | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Ogawa, H; Sekiguchi, H; Yamaguchi, J | 2 |
| Chaitman, BR; Schwartz, GG | 1 |
| Auer, R; Carballo, D; Carballo, S; Gencer, B; Heg, D; Klingenberg, R; Koskinas, KC; Lüscher, TF; Mach, F; Matter, CM; Nanchen, D; Räber, L; Rodondi, N; Windecker, S | 1 |
| Li, D; McCaw, ZR; Wei, LJ | 1 |
| Bach, RG; Blazing, MA; Cannon, CP | 1 |
| Lütjohann, D; Sijbrands, EJG; Weingärtner, O | 1 |
| Bruckert, E; Buonvino, C; Chopard, R; Farnier, M; Ferrières, J; Guillon, B; Krempf, M; Meneveau, N; Puymirat, E; Schiele, F | 1 |
| Fujimoto, K; Fujisue, K; Hokimoto, S; Ishihara, M; Izumiya, Y; Kaikita, K; Koide, S; Matsui, K; Matsumura, T; Matsuyama, K; Miyazaki, T; Morikami, Y; Nagamatsu, S; Nakamura, S; Nakao, K; Ogawa, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Arashi, H; Hagiwara, N; Nakazawa, M; Ogawa, H; Yamaguchi, J | 1 |
| Angiolillo, DJ; Cao, D; Claessen, BE; Gibson, CM; Guedeney, P; Lepor, N; Mehran, R | 1 |
| Bruckert, E; Desamericq, G; Gusto, G; Khachatryan, A; Ngo, P; Sorio-Vilela, F | 1 |
| Banach, M; Bunc, M; Dudek, D; Durak-Nalbantic, A; Dyrbus, K; Fedacko, J; Fras, Z; Gaita, D; Gierlotka, M; Jarai, Z; Magda, SL; Margetic, E; Margoczy, R; Ostadal, P; Pella, D; Penson, PE; Reiner, Ž; Trbusic, M; Udroiu, CA; Vlachopoulos, C; Vrablik, M; Vulic, D | 1 |
| Arashi, H; Fujii, S; Hagiwara, N; Im, J; Kawada-Watanabe, E; Matsui, Y; Mori, F; Ogawa, H; Otsuki, H; Sekiguchi, H; Yamaguchi, J | 1 |
| Arashi, H; Hagiwara, N; Ogawa, H; Ogiso, M; Otsuki, H; Sekiguchi, H; Yamaguchi, J | 1 |
| Cui, Y; Jin, S; Li, Y; Nie, X; Yuan, J; Zhao, L | 1 |
| Fujisue, K; Tsujita, K | 1 |
| Arashi, H; Endoh, Y; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Nakao, K; Ogawa, H; Oka, T; Saito, K; Tanaka, H; Tobaru, T; Uchida, T; Yamaguchi, J | 1 |
| Daugherty, SL; Downs, JR; Maddox, TM; Masoudi, FA; Rumsfeld, JS; Tang, F; Virani, SS | 1 |
| Blazing, MA; Braunwald, E; Cannon, CP; Chinnakondepalli, K; Cohen, DJ; Davies, G; Giugliano, RP; Magnuson, EA; Mark, DB; Pokharel, Y; Vilain, K; Wang, K | 1 |
| Humphries, KH; Mancini, GBJ | 1 |
| Japaridze, L; Sadunishvili, M | 1 |
| Ako, J; Arai, H; Harada-Shiba, M; Hirayama, A; Nakamura, M; Nohara, A; Uno, K | 1 |
| Alahmari, A; Almalki, ZS; Alotaibi, N; Guo, JJ; Thaibah, H | 1 |
| Blazing, MA; Braunwald, E; Clare, RM; Fanaroff, AC; Giugliano, RP; Lokhnygina, Y; Navar, AM; Roe, MT; Tershakovec, AM; Wiviott, SD | 1 |
| Auer, R; Carballo, D; Carballo, S; Gencer, B; Heg, D; Karagiannis, A; Klingenberg, R; Koskinas, KC; Lüscher, TF; Mach, F; Matter, CM; Nanchen, D; Räber, L; Rodondi, N; Windecker, S | 1 |
| Amano, T; Fujiwara, H; Hibi, K; Ishii, H; Kawasaki, M; Kimura, K; Koshida, R; Kozuma, K; Miyamoto, T; Morino, Y; Morita, S; Murohara, T; Otsuji, Y; Ozaki, Y; Sata, M; Sato, K; Sonoda, S | 1 |
| Arashi, H; Endo, Y; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Nakao, K; Ogawa, H; Oka, T; Saito, K; Sekiguchi, H; Tanaka, H; Tobaru, T; Uchida, T; Yamaguchi, J | 1 |
| Deloughery, EP; Prasad, V | 1 |
| Borghi, C; Del Pinto, R; Ferri, C | 1 |
| Michalopoulou, H; Thomopoulos, C | 1 |
| Bertomeu-González, V; Cordero, A; Rodriguez-Mañero, M | 1 |
| Koh, KK | 1 |
| Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Park, JG; Wiviott, SD | 1 |
| Pitha, J | 1 |
| Laufs, U; Lütjohann, D; Schulze, PC; Weingärtner, O | 1 |
| Arashi, H; Hagiwara, N; Kanbayashi, K; Kawada-Watanabe, E; Ogawa, H; Sekiguchi, H; Yamaguchi, J | 1 |
| Blazing, M; Bonaca, MP; Braunwald, E; Cannon, C; Giugliano, R; Gutierrez, JA; Park, JG; Tershakovec, A; White, J | 1 |
| Chitose, T; Fujisue, K; Harada-Shiba, M; Hokimoto, S; Hori, M; Izumiya, Y; Kaikita, K; Kajiwara, I; Nagamatsu, S; Ogawa, H; Ono, T; Sakamoto, K; Shirahama, R; Sueta, D; Takashio, S; Tsujita, K; Yamamoto, E | 1 |
| Ahmad, T; Blazing, MA; Desai, NR; Lokhnygina, Y; Roe, MT; Sharma, A; Sun, JL | 1 |
| Huang, Z; Li, Q; Li, X; Ye, W; Zhang, Q | 1 |
| Libby, P; Qamar, A | 1 |
| Gotto, AM | 1 |
| Alessi, MC; Bonnet, G; Bonnet, JL; Cuisset, T; Deharo, P; Grosdidier, C; Morange, P; Pankert, M; Quilici, J; Verdier, V | 1 |
| Blazing, MA; Braunwald, E; Califf, RM; Cannon, CP; Giugliano, RP; McCagg, A; Musliner, TA; Reist, C; Tershakovec, AM; White, JA | 1 |
| Einecke, D | 1 |
| Parhofer, K | 1 |
| Špinar, J; Špinarová, L; Vítovec, J | 1 |
| Packard, C; Stezhka, T | 1 |
| Li, L; Li, Y; Shen, J; Shen, Y; Su, F; Zhang, D; Zhang, M | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Califf, RM; Cannon, CP; Darius, H; De Ferrari, GM; De Lucca, P; Giugliano, RP; Im, K; Jukema, JW; Lewis, BS; McCagg, A; Musliner, TA; Ophuis, TO; Reist, C; Ruzyllo, W; Tershakovec, AM; Theroux, P; White, JA; Wiviott, SD | 1 |
| Akeroyd, JM; Ballantyne, CM; Gillette, MA; Maddox, TM; Michael Ho, P; Nambi, V; Petersen, LA; Rumsfeld, J; Virani, SS | 1 |
| Frishman, WH | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM; White, JA; Zhou, J | 1 |
| Blumenthal, RS; Martin, SS; Michos, ED | 2 |
| Ferguson, LD; Logue, J | 1 |
| Lancellotti, P; Pierard, LA; Scheen, AJ | 1 |
| Greco, C; Lina, D; Menozzi, A; Urbinati, S | 1 |
| Goldstein, MR; Mascitelli, L | 1 |
| Poli, A | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Dellborg, M; Giugliano, RP; Im, K; Isaza, D; Kher, U; Lokhnygina, Y; Lopez-Sendon, J; Murphy, SA; Reist, C; Tershakovec, AM; White, JA | 1 |
| Murphy, J; Wright, RS | 1 |
| Granger, CB; Lopes, RD; Pesaro, AE | 1 |
| Robinson, JG | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Giugliano, RP; Murphy, SA; Tershakovec, AM; White, J; Zhou, J | 1 |
| Correia, LC | 1 |
| Japaridze, L; Megreladze, I; Sadunishvili, M | 1 |
| Banach, M; Nikolic, D; Rizzo, M; Toth, PP | 1 |
| Abrignani, MG; Arca, M; Colivicchi, F; Gulizia, MM; Mureddu, GF; Nardi, F; Perna, GP; Riccio, C | 1 |
| Fujimoto, K; Hokimoto, S; Ishihara, M; Kaikita, K; Koide, S; Komura, N; Matsui, K; Matsumura, T; Matsuyama, K; Morikami, Y; Nakamura, N; Nakamura, S; Nakao, K; Ogawa, H; Oka, H; Oshima, S; Sakaino, N; Sakamoto, K; Shimomura, H; Sugiyama, S; Sumida, H; Tsujita, K; Tsunoda, R; Yamamoto, N; Yamanaga, K; Yamashita, T | 1 |
| Arashi, H; Hagiwara, N; Kawada-Watanabe, E; Koyanagi, R; Matsui, K; Ogawa, H; Yamaguchi, J | 1 |
| Gartlehner, G; Glechner, A; Kaminski-Hartenthaler, A; Mahlknecht, P; Nußbaumer, B | 1 |
| Blazing, MA; Bohula, EA; Braunwald, E; Cannon, CP; Eisen, A; Giugliano, RP; Murphy, SA; Park, JG; White, JA | 1 |
| Adamska, U; Adamski, P; Koziński, M; Kubica, J; Ostrowska, M | 1 |
| Bays, HE; Chaudhari, U; Jones, PH; Lorenzato, C; Miller, K; Pordy, R; Robinson, JG | 1 |
| Ballantyne, CM; Blazing, MA; Braunwald, E; Cannon, CP; de Lemos, JA; Giugliano, RP; Lewis, BS; Lokhnygina, Y; McCagg, A; Musliner, TA; Reist, C; Tershakovec, AM; Tonkin, A; White, JA | 1 |
| Chu, Y; Hao, H; Li, J; Liu, Z; Xu, D; Yin, C | 1 |
| Chen, PY; Chien, KL; Choo, DW; Chou, CH; Ho, W; Lin Wu, FL; Lin, ZF; Wang, J; Wang, YW; Wu, YJ | 1 |
| Blazing, MA; Bohula, EA; Brady, AJ; Braunwald, E; Cannon, CP; Giugliano, RP; He, P; Kesaniemi, YA; Mitchel, Y; Morrow, DA; Murphy, SA; Park, JG; Pedersen, TR; White, JA | 1 |
| Deng, SB; Du, JL; Gao, YL; Jing, XD; Liu, YJ; Nie, HJ; Ran, D; She, Q | 1 |
| Machnik, A; Potaczek, DP; Tracz, W; Undas, A; Wypasek, E; Zmudka, K | 1 |
| Boyden, T; Khanderia, U; Regal, RE; Rubenfire, M | 1 |
| Bai, CH; Gau, CS; Hsiao, FY; Lin, CF; Shen, LJ; Wu, FL | 1 |
| Padial, LR | 1 |
12 review(s) available for ezetimibe and Acute Coronary Syndrome
| Article | Year |
|---|---|
Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Disease; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2023 |
Benefit of Combination Ezetimibe/Simvastatin Among High-Risk Populations: Lessons from the IMPROVE-IT Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin; Treatment Outcome | 2023 |
Effectiveness of lipid-lowering therapy on mortality and major adverse cardiovascular event outcomes in patients undergoing percutaneous coronary intervention: a network meta-analysis of randomised controlled trials.
Topics: Acute Coronary Syndrome; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Network Meta-Analysis; Percutaneous Coronary Intervention; Rosuvastatin Calcium | 2023 |
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Cholesterol, LDL; Cost-Benefit Analysis; Dicarboxylic Acids; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipids; Male; Middle Aged; Myocardial Ischemia; PCSK9 Inhibitors; Practice Guidelines as Topic; Risk Reduction Behavior; RNA, Small Interfering; Secondary Prevention | 2020 |
Effect of More Intensive LDL-C-Lowering Therapy on Long-term Cardiovascular Outcomes in Early-Phase Acute Coronary Syndrome: A Systematic Review and Meta-analysis.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2021 |
Current status of lipid management in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipid Metabolism; PCSK9 Inhibitors; Plaque, Atherosclerotic | 2017 |
Low-Density Lipoprotein Cholesterol After an Acute Coronary Syndrome: How Low to Go?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9; Proprotein Convertases; Randomized Controlled Trials as Topic | 2019 |
IMPROVE-IT: what have we learned?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Simvastatin; Treatment Outcome | 2016 |
Ezetimibe-Statin Combination Therapy.
Topics: Acute Coronary Syndrome; Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Causality; Comorbidity; Death, Sudden, Cardiac; Diabetes Mellitus; Drug Combinations; Drug-Related Side Effects and Adverse Reactions; Evidence-Based Medicine; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Risk Factors; Survival Rate; Treatment Outcome | 2016 |
New directions for pharmacotherapy in the treatment of acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Antibodies, Monoclonal; Anticholesteremic Agents; Clinical Trials as Topic; Drug Discovery; Ezetimibe; Humans; PCSK9 Inhibitors; Platelet Aggregation Inhibitors; Purinergic P2Y Receptor Antagonists; Thrombosis; Treatment Outcome | 2016 |
The ezetimibe controversy: implications for clinical practice.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Neoplasms; Plaque, Atherosclerotic | 2011 |
Ezetimibe plus simvastatin cardiovascular outcomes study program.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Aortic Valve Stenosis; Atherosclerosis; Azetidines; Disease Progression; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Kidney Failure, Chronic; Simvastatin; Treatment Outcome | 2008 |
37 trial(s) available for ezetimibe and Acute Coronary Syndrome
| Article | Year |
|---|---|
Baseline Low-Density Lipoprotein Cholesterol and Clinical Outcomes of Combining Ezetimibe With Statin Therapy in IMPROVE-IT.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin | 2021 |
Effect of the Early Application of Evolocumab on Blood Lipid Profile and Cardiovascular Prognosis in Patients with Extremely High-Risk Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Apolipoproteins; Atorvastatin; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Percutaneous Coronary Intervention; Prognosis; Proprotein Convertase 9; Prospective Studies; Treatment Outcome | 2022 |
Association of Serial High-Sensitivity Cardiac Troponin T With Subsequent Cardiovascular Events in Patients Stabilized After Acute Coronary Syndrome: A Secondary Analysis From IMPROVE-IT.
Topics: Acute Coronary Syndrome; Biomarkers; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Male; Middle Aged; Troponin T | 2022 |
Polyunsaturated Fatty Acid Impact on Clinical Outcomes in Acute Coronary Syndrome Patients With Dyslipidemia: Subanalysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Arachidonic Acid; Cholesterol, LDL; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Ezetimibe; Fatty Acids, Unsaturated; Female; Humans; Male; Middle Aged; Mortality; Myocardial Infarction; Myocardial Revascularization; Prognosis; Quinolines; Risk Assessment; Stroke | 2019 |
Targeting high-sensitivity C-reactive protein levels in acute coronary syndrome patients undergoing contemporary lipid-lowering therapy: a sub-analysis of the HIJ-PROPER trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; C-Reactive Protein; Dyslipidemias; Ezetimibe; Female; Humans; Male; Middle Aged; Quinolines; Single-Blind Method | 2020 |
Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Simvastatin | 2020 |
Effects of Statin Plus Ezetimibe on Coronary Plaques in Acute Coronary Syndrome Patients with Diabetes Mellitus: Sub-Analysis of PRECISE-IVUS Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Coronary Vessels; Diabetes Mellitus, Type 2; Drug Monitoring; Ezetimibe; Female; Humans; Male; Plaque, Atherosclerotic; Treatment Outcome; Ultrasonography, Interventional | 2021 |
Lower levels of high-density lipoprotein cholesterol are associated with increased cardiovascular events in patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Cardiovascular Diseases; Cholesterol, HDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Prospective Studies; Quinolines; Treatment Outcome | 2020 |
Baseline low-density lipoprotein cholesterol predicts the benefit of adding ezetimibe on statin in statin-naïve acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Cholesterol, LDL; Endpoint Determination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Treatment Outcome | 2021 |
Association between anemia and mortality in patients with acute coronary syndrome treated with percutaneous coronary intervention and contemporary lipid-lowering therapy.
Topics: Acute Coronary Syndrome; Anemia; Dyslipidemias; Ezetimibe; Female; Humans; Male; Percutaneous Coronary Intervention; Treatment Outcome | 2021 |
Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Non-ST Elevated Myocardial Infarction; Prospective Studies; Quinolines; ST Elevation Myocardial Infarction; Treatment Outcome | 2017 |
Impact of Ezetimibe on the Rate of Cardiovascular-Related Hospitalizations and Associated Costs Among Patients With a Recent Acute Coronary Syndrome: Results From the IMPROVE-IT Trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial).
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Follow-Up Studies; Forecasting; Hospital Costs; Hospitalization; Humans; Male; Middle Aged; Treatment Outcome | 2017 |
The short-term effect of atorvastatin plus ezetimibe therapy versus atorvastatin monotherapy on clinical outcome in acute coronary syndrome patients by gender.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Prospective Studies; Treatment Outcome | 2017 |
Cost-Effectiveness of Simvastatin Plus Ezetimibe for Cardiovascular Prevention in Patients With a History of Acute Coronary Syndrome: Analysis of Results of the IMPROVE-IT Trial.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Brain Ischemia; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Forecasting; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Quality-Adjusted Life Years; Saudi Arabia; Simvastatin; Treatment Outcome | 2018 |
Competing Risks of Cardiovascular Versus Noncardiovascular Death During Long-Term Follow-Up After Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Age Distribution; Aged; Cause of Death; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Double-Blind Method; Ezetimibe; Female; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Prognosis; Risk Assessment; Risk Factors; Sex Distribution; Simvastatin; Survival Rate; Time Factors; United States | 2017 |
Effects of Ezetimibe-Statin Combination Therapy on Coronary Atherosclerosis in Acute Coronary Syndrome.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Cholesterol, LDL; Disease Progression; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Percutaneous Coronary Intervention; Plaque, Atherosclerotic; Quinolines; Ultrasonography, Interventional | 2018 |
Predictive Value of Baseline High-Sensitivity C-Reactive Protein Level and Renal Function for Patients With Acute Coronary Syndrome Undergoing Aggressive Lipid-Lowering Therapy: A Subanalysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Prospective Studies; Quinolines; Renal Insufficiency; Single-Blind Method; Time Factors | 2018 |
Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Vascular Diseases | 2018 |
Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT).
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cause of Death; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; North America; Phenotype; Risk Assessment; Risk Factors; Simvastatin; Survival Rate; Treatment Outcome | 2019 |
Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies; Pyrimidines; Rosuvastatin Calcium; Sulfonamides | 2014 |
[IMPROVE-IT Study proves effectiveness of ezetimib. The Higgs particle of lipidologists].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Follow-Up Studies; Heptanoic Acids; Humans; Hypercholesterolemia; Pravastatin; Pyrroles; Simvastatin | 2014 |
[IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (studie IMPROVE-IT)].
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Double-Blind Method; Drug Combinations; Drug Therapy, Combination; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Female; Humans; Male; Middle Aged; Myocardial Infarction; Simvastatin | 2014 |
Combination therapy analysis of ezetimibe and statins in Chinese patients with acute coronary syndrome and type 2 diabetes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; China; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Pravastatin; Rosuvastatin Calcium; Simvastatin | 2015 |
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kaplan-Meier Estimate; Male; Middle Aged; Simvastatin; Triglycerides | 2015 |
Achievement of dual low-density lipoprotein cholesterol and high-sensitivity C-reactive protein targets more frequent with the addition of ezetimibe to simvastatin and associated with better outcomes in IMPROVE-IT.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Cerebral Revascularization; Cholesterol, LDL; Comorbidity; Creatinine; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Electrocardiography; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Simvastatin; Treatment Outcome | 2015 |
[ACUTE CORONARY SYNDROME AND LIPID-LOWERING THERAPY. DOES THE IMPROVE-IT STUDY MAKE ANY DIFFERENCE?].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dose-Response Relationship, Drug; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prognosis; Simvastatin; Treatment Outcome | 2015 |
Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Male; Middle Aged; Myocardial Infarction; Simvastatin; Survival Rate; Time Factors; Treatment Outcome; United States | 2016 |
[Approval extension for statin plus ezetimib].
Topics: Acute Coronary Syndrome; Drug Approval; Drug Therapy, Combination; Ezetimibe; Humans; Hypercholesterolemia; Simvastatin | 2016 |
COMBINATION THERAPY EFFECTIVENESS OF EZETIMIBE AND ATORVASTATIN IN PATIENTS WITH ACUTE CORONARY SYNDROME.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Prospective Studies | 2016 |
Lipid profile associated with coronary plaque regression in patients with acute coronary syndrome: Subanalysis of PRECISE-IVUS trial.
Topics: Acute Coronary Syndrome; Aged; Atorvastatin; Biomarkers; Cholesterol; Cholesterol, LDL; Coronary Angiography; Coronary Artery Disease; Disease Progression; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Male; Middle Aged; Plaque, Atherosclerotic; Prospective Studies; Treatment Outcome; Ultrasonography, Interventional | 2016 |
Rationale, design features, and baseline characteristics: The Heart Institute of Japan-PRoper level of lipid lOwering with Pitavastatin and Ezetimibe in acute coRonary syndrome (HIJ-PROPER).
Topics: Acute Coronary Syndrome; Aged; Cholesterol, LDL; Coronary Angiography; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypolipidemic Agents; Japan; Male; Middle Aged; Prospective Studies; Quinolines | 2017 |
The benefit of adding ezetimibe to statin therapy in patients with prior coronary artery bypass graft surgery and acute coronary syndrome in the IMPROVE-IT trial.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Coronary Artery Bypass; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Simvastatin; Treatment Outcome | 2016 |
On-treatment analysis of the Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT).
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Monitoring; Drug Synergism; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Simvastatin; Treatment Outcome | 2016 |
Therapeutic effects of atorvastatin and ezetimibe compared with double-dose atorvastatin in very elderly patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Age Factors; Aged, 80 and over; Anticholesteremic Agents; Atorvastatin; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Prognosis | 2017 |
Effectiveness of a combination of ezetimibe and statins in patients with acute coronary syndrome and multiple comorbidities: A 6-year population-based cohort study.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Comorbidity; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Population Surveillance; Propensity Score; Survival Rate; Taiwan; Time Factors; Treatment Outcome | 2017 |
A randomized, controlled comparison of different intensive lipid-lowering therapies in Chinese patients with non-ST-elevation acute coronary syndrome (NSTE-ACS): Ezetimibe and rosuvastatin versus high-dose rosuvastatin.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; C-Reactive Protein; China; Cholesterol, LDL; Dose-Response Relationship, Drug; Drug Monitoring; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Ezetimibe; Female; Humans; Male; Middle Aged; Rosuvastatin Calcium | 2017 |
Ezetimibe combined with simvastatin compared with simvastatin alone results in a greater suppression of oxidative stress and enhanced fibrinolysis in patients after acute coronary events.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Azetidines; Double-Blind Method; Drug Therapy, Combination; Ezetimibe; Female; Fibrinolysis; Humans; Lipids; Male; Middle Aged; Oxidative Stress; Simvastatin; Treatment Outcome; Young Adult | 2011 |
53 other study(ies) available for ezetimibe and Acute Coronary Syndrome
| Article | Year |
|---|---|
Effectiveness of hospital lipid-lowering protocol of intensive lipid-lowering therapy for patients with acute coronary syndrome.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Ezetimibe; Hospitals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Retrospective Studies; Treatment Outcome | 2022 |
[Importance of the individualized care process in a patient with recurrent acute coronary syndrome, multiple comorbidities and depressive syndrome].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Depressive Disorder; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Rosuvastatin Calcium | 2022 |
Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Cost-Benefit Analysis; Cost-Effectiveness Analysis; Ezetimibe; Homozygous Familial Hypercholesterolemia; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Proprotein Convertase 9 | 2023 |
Achievement of ESC/EAS LDL-C treatment goals after an acute coronary syndrome with statin and alirocumab.
Topics: Acute Coronary Syndrome; Cholesterol, LDL; Double-Blind Method; Ezetimibe; Goals; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2022 |
[The importance of intensive lipid-lowering therapy after acute coronary syndrome: changing the paradigm to improve the achievement of targets].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Treatment Outcome | 2022 |
[Managing lipid risk in acute coronary syndrome patients in the real world: results from the BEST consensus].
Topics: Acute Coronary Syndrome; Consensus; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Proprotein Convertase 9 | 2023 |
Statin versus ezetimibe-statin for incident atrial fibrillation among patients with type 2 diabetes mellitus with acute coronary syndrome and acute ischemic stroke.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; Atrial Fibrillation; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Stroke; Simvastatin; Stroke; Treatment Outcome | 2023 |
Upfront Combination of Statin and Ezetimibe for Patients With Acute Coronary Syndrome: Time for a New Approach?
Topics: Acute Coronary Syndrome; Combined Modality Therapy; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Propensity Score | 2023 |
Intensive Statin Therapy Versus Upfront Combination Therapy of Statin and Ezetimibe in Patients With Acute Coronary Syndrome: A Propensity Score Matching Analysis Based on the PL-ACS Data.
Topics: Acute Coronary Syndrome; Atorvastatin; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Propensity Score; Rosuvastatin Calcium | 2023 |
Initiating PCSK9 Inhibition in Hospital for ACS: We Can, But Does That Mean We Should?
Topics: Acute Coronary Syndrome; Antibodies, Monoclonal, Humanized; Cholesterol, LDL; Ezetimibe; Humans; Proprotein Convertase 9 | 2019 |
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin | 2020 |
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin | 2020 |
Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Simvastatin | 2020 |
An innovative lipid-lowering approach to enhance attainment of low-density lipoprotein cholesterol goals.
Topics: Acute Coronary Syndrome; Aged; Algorithms; Anticholesteremic Agents; Biomarkers; Cholesterol, LDL; Ezetimibe; Female; Follow-Up Studies; Hospitalization; Humans; Male; Patient Compliance; Prognosis; Prospective Studies | 2020 |
Patient characteristics, treatment patterns, and adherence to lipid-lowering therapies following an acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Drug Therapy, Combination; Dyslipidemias; Ezetimibe; Female; France; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Medication Adherence; Middle Aged; Percutaneous Coronary Intervention; Practice Patterns, Physicians'; Registries; Retrospective Studies; Time Factors; Treatment Outcome | 2020 |
Optimal use of lipid-lowering therapy after acute coronary syndromes: A Position Paper endorsed by the International Lipid Expert Panel (ILEP).
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atherosclerosis; Disease Management; Ezetimibe; Humans; Lipids; PCSK9 Inhibitors | 2021 |
Applicability of the IMPROVE-IT Trial to Current Patients With Acute Coronary Syndrome: An NCDR Research to Practice Project.
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Anticholesteremic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Female; Humans; Male; Middle Aged; Registries; Simvastatin | 2017 |
Reduction of LDL-C-related residual cardiovascular risk with ezetimibe: are mechanistic considerations warranted in practice?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Humans; Prospective Studies; Quinolines; Risk Factors | 2017 |
Exploration into lipid management and persistent risk in patients hospitalised for acute coronary syndrome in Japan (EXPLORE-J): protocol for a prospective observational study.
Topics: Acute Coronary Syndrome; Angina, Unstable; Anticholesteremic Agents; Ezetimibe; Fibric Acids; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Incidence; Ischemic Attack, Transient; Japan; Multicenter Studies as Topic; Myocardial Infarction; Myocardial Revascularization; Observational Studies as Topic; PCSK9 Inhibitors; Prevalence; Proprotein Convertase 9; Prospective Studies; Registries; Research Design; Risk Factors; Stroke | 2017 |
Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Apoptosis; Cardiology; Cholesterol, LDL; Dose-Response Relationship, Drug; Eligibility Determination; Europe; Ezetimibe; Female; Follow-Up Studies; Humans; Male; Middle Aged; PCSK9 Inhibitors; Practice Guidelines as Topic; Prospective Studies; Societies, Medical; Time Factors; Treatment Outcome; United States | 2017 |
Baseline serum sitosterol level as predictor of adverse clinical events in acute coronary syndrome patients with dyslipidaemia: A sub-analysis of HIJ-PROPER.
Topics: Acute Coronary Syndrome; Aged; Biomarkers; Cholesterol, LDL; Dyslipidemias; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Japan; Male; Middle Aged; Predictive Value of Tests; Quinolines; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Assessment; Risk Factors; Sitosterols; Time Factors; Treatment Outcome | 2018 |
If the IMPROVE-IT Trial Was Positive, as Reported, Why Did the FDA Denied Expanded Approval for Ezetimibe and Simvastatin? An Explanation of the Tipping Point Analysis.
Topics: Acute Coronary Syndrome; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Simvastatin | 2018 |
Letter by Del Pinto et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Letter by Thomopoulos and Michalopoulou Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Letter by Cordero et al Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Letter by Koh Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Response by Bohula et al to Letters Regarding Article, "Prevention of Stroke With the Addition of Ezetimibe to Statin Therapy in Patients With Acute Coronary Syndrome in IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial)".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Stroke | 2018 |
Improved management of patients after acute coronary syndrome: using nonalcoholic fatty liver disease fibrosis score and ezetimibe?
Topics: Acute Coronary Syndrome; Azetidines; Ezetimibe; Humans; Liver; Liver Cirrhosis; Non-alcoholic Fatty Liver Disease | 2018 |
Call for an ezetimibe effectiveness test.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Dyslipidemias; Ezetimibe; Humans; Sitosterols | 2018 |
Reply to: "Call for an ezetimibe effectivess test".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Dyslipidemias; Ezetimibe; Humans; Sitosterols | 2018 |
Coronary Artery Plaque Regression by a PCSK9 Antibody and Rosuvastatin in Double-heterozygous Familial Hypercholesterolemia with an LDL Receptor Mutation and a PCSK9 V4I Mutation.
Topics: Acute Coronary Syndrome; Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Heterozygote; Humans; Hyperlipoproteinemia Type II; Male; Mutation; Plaque, Amyloid; Proprotein Convertase 9; Receptors, LDL; Rosuvastatin Calcium | 2018 |
Efficacy and Safety of Ezetimibe in Combination with Atorvastatin for Acute Coronary Syndrome Patients Accompanied with Type 2 Diabetes: A Single-Center, Non-randomized Cohort Study.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Cohort Studies; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Ezetimibe; Female; Humans; Lipids; Male; Middle Aged; Myocardium | 2019 |
Intensive Lipid Lowering in Elderly Patients.
Topics: Acute Coronary Syndrome; Aged; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipids; Simvastatin | 2019 |
Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.
Topics: Acute Coronary Syndrome; Aged; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Simvastatin | 2014 |
[Which patient will now actually benefit from ezetimib?].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Randomized Controlled Trials as Topic | 2014 |
Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe; Humans; Simvastatin | 2015 |
Implications for Ezetimibe Therapy Use Based on IMPROVE-IT Criteria.
Topics: Acute Coronary Syndrome; Adult; Aged; Anticholesteremic Agents; Drug Therapy, Combination; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome; United States; United States Department of Veterans Affairs | 2015 |
Can Clinicians Improve on the Effectiveness of Statins with Additional Lipid-lowering Therapies?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Patient Selection; Simvastatin | 2015 |
Bringing back targets to "IMPROVE" atherosclerotic cardiovascular disease outcomes: the duel for dual goals; are two targets better than one?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2015 |
Has IMPROVE-IT improved cardiovascular outcome?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cardiovascular Diseases; Ezetimibe; Humans; Randomized Controlled Trials as Topic; Treatment Outcome | 2015 |
[The IMPROVE-IT trial].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
[The IMPROVE-IT trial showed no favorable effects on well-defined and clinically relevant endpoints].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
[Letter].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Randomized Controlled Trials as Topic; Simvastatin; Treatment Outcome | 2015 |
PROVE-IT to IMPROVE-IT: Why LDL-C Goals Still Matter in Post-ACS Patients.
Topics: Acute Coronary Syndrome; Ezetimibe; Female; Humans; Male; Myocardial Infarction; Simvastatin | 2016 |
Reduction of ischemic events in Improved Reduction of Outcomes: Vytorin Efficacy International Trial: Intensive cholesterol lowering or ezetimibe antithrombotic effects?
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Brazil; Cholesterol; Dose-Response Relationship, Drug; Ezetimibe; Ezetimibe, Simvastatin Drug Combination; Humans; Incidence; Randomized Controlled Trials as Topic; Treatment Outcome | 2016 |
Letter by Robinson Regarding Articles, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?" and "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Se
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2016 |
Response to Letter Regarding Article, "Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2016 |
Response to the Letter Regarding Article, "Bringing Back Targets to 'IMPROVE' Atherosclerotic Cardiovascular Disease Outcomes: The Duel for Dual Goals; Are Two Targets Better Than One?".
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; C-Reactive Protein; Cholesterol, LDL; Ezetimibe; Female; Humans; Male; Simvastatin | 2016 |
Ezetimibe: Clinical and Scientific Meaning of the IMPROVE-IT Study.
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Clinical Trials as Topic; Drug Therapy, Combination; Evidence-Based Medicine; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Numbers Needed To Treat; Treatment Outcome | 2016 |
[ANMCO Position paper: Clinical management of hypercholesterolemia in patients with acute coronary syndrome].
Topics: Acute Coronary Syndrome; Anticholesteremic Agents; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Italy; Treatment Outcome | 2016 |
Safety of Alirocumab (A PCSK9 Monoclonal Antibody) from 14 Randomized Trials.
Topics: Acute Coronary Syndrome; Aged; Angina, Unstable; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; Back Pain; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Comorbidity; Coronary Disease; Diabetes Mellitus, Type 2; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Influenza, Human; Middle Aged; Myocardial Infarction; Nasopharyngitis; Pruritus; Randomized Controlled Trials as Topic; Respiratory Tract Infections; Stroke; Urinary Tract Infections | 2016 |
Atherothrombotic Risk Stratification and Ezetimibe for Secondary Prevention.
Topics: Acute Coronary Syndrome; Aged; Ezetimibe; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myocardial Infarction; Prospective Studies; Risk Assessment; Secondary Prevention; Simvastatin; Treatment Outcome | 2017 |
Impact of ezetimibe coadministered with statins on cardiovascular events following acute coronary syndrome: a 3-year population-based retrospective cohort study in Taiwan.
Topics: Acute Coronary Syndrome; Angioplasty, Balloon, Coronary; Anticholesteremic Agents; Azetidines; Cohort Studies; Drug Therapy, Combination; Ezetimibe; Female; Hospitalization; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Proportional Hazards Models; Retrospective Studies; Stents; Taiwan; Treatment Outcome | 2011 |